Vavricka John 4

4 · Atea Pharmaceuticals, Inc. · Filed Feb 4, 2025

Form 4

Period: 2025-01-31

Chief Commercial Officer

Transactions

Exercise/Conversion
Common Stock
2025-01-31+33,333→ 54,848 total
Award
Common Stock
2025-01-31+8,750→ 63,598 total
Exercise/Conversion
Restricted Stock Units
2025-01-31−33,333→ 33,333 total
→ Common Stock (33,333 underlying)
Award
Restricted Stock Units
2025-01-31+8,750→ 8,750 total
→ Common Stock (8,750 underlying)
Award
Stock Option (Right to Buy)
2025-01-31+132,800→ 132,800 total
Exercise: $3.06Exp: 2035-01-30→ Common Stock (132,800 underlying)
Tax Payment
Common Stock
2025-01-31$3.06/sh−11,517$35,242→ 52,081 total

Holdings

Footnotes (5)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").
[F3]The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
[F4]Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.
[F5]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

Documents

1 file